Compare MSS & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSS | ARTL |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.3M |
| IPO Year | 2023 | N/A |
| Metric | MSS | ARTL |
|---|---|---|
| Price | $1.21 | $2.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 689.8K | 444.5K |
| Earning Date | 03-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,217,480.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.01 | N/A |
| 52 Week Low | $0.11 | $0.90 |
| 52 Week High | $3.96 | $28.60 |
| Indicator | MSS | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 69.38 | 33.65 |
| Support Level | $0.24 | $1.62 |
| Resistance Level | $3.96 | $3.67 |
| Average True Range (ATR) | 0.17 | 0.27 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 57.43 | 1.73 |
Maison Solutions Inc is a fast-growing, specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly members of Asian-American communities. It is committed to providing Asian fresh produce, meat, seafood, and other daily necessities in a manner that caters to traditional Asian-American family values and cultural norms, while also accounting for the new and faster-paced lifestyle of younger generations and the diverse communities in which it operates. The company's merchandise includes fresh and, meats, seafood, and other groceries that are not found in mainstream supermarkets, including a variety of Asian vegetables and fruits such as broccoli, bitter melon, winter gourd, Shanghai baby bok choy, longan, and lychee.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.